Abbott SVP granted 13,255 restricted shares

ORVILLE JACOB A reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

ORVILLE JACOB A reported acquisition or exercise transactions in this Form 4 filing.

ABBOTT LABORATORIES Senior Vice President Orville Jacob A received a grant of 13,255 common shares as a restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 2-year term, with one-half vesting in any one year beginning on March 23, 2027.

Following this grant, he directly holds 50,493 common shares. The award includes the right to have shares withheld to cover tax obligations rather than paying taxes in cash.

Insider Trade Summary

Grant/Award: 13,255 shares

Grant/Award 1 txn

Insider ORVILLE JACOB A

Role Senior Vice President

Type	Security	Shares	Price	Value
Grant/Award	Common shares without par value	13,255	$0.00	$0.00

Holdings After Transaction: Common shares without par value — 50,493 shares (Direct)

Footnotes (1)

1. F1. These shares represent a restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 2-year term, with 1/2 of the award vesting in any one year, beginning on March 23, 2027. The award includes the right to have shares withheld for tax purposes.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Abbott (ABT) report for Orville Jacob A?

Abbott reported that Senior Vice President Orville Jacob A acquired 13,255 common shares through a restricted stock award. The shares were granted at no cash cost as part of the Abbott Laboratories 2017 Incentive Stock Program, reflecting equity-based executive compensation.

How many Abbott (ABT) shares were granted and what is Orville Jacob A’s holding after the award?

He was granted 13,255 common shares in this transaction. After the grant, his directly held position increased to 50,493 common shares, as reported in the filing, giving investors a clearer view of his current equity stake in Abbott Laboratories.

What are the vesting terms and schedule for the Abbott (ABT) restricted stock award?

The restricted stock award has a 2-year term. One-half of the 13,255 granted shares may vest in any one year, with vesting beginning on March 23, 2027, meaning the shares become earned and transferable over that period according to program rules.

What is the nature of the Abbott Laboratories 2017 Incentive Stock Program award reported for ABT?

The filing describes the grant as a restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. Such awards give executives common shares subject to vesting conditions, aligning compensation with long-term company performance and shareholder interests over the award’s two-year term.

Does the Abbott (ABT) restricted stock award allow share withholding for taxes?

Yes. The award explicitly includes the right to have shares withheld for tax purposes. Instead of paying taxes in cash when portions vest, some of the granted shares can be automatically withheld to satisfy tax obligations associated with the vesting event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/25/2026 - 06:56 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ORVILLE JACOB A

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	03/23/2026		A		13,255(1)	A	$0	50,493	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent a restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 2-year term, with 1/2 of the award vesting in any one year, beginning on March 23, 2027. The award includes the right to have shares withheld for tax purposes.

	/s/ Jacob A. Orville, by Jessica H. Paik, Attorney-in-Fact	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)